Jack Sadowsky
A5092965181- Radiopharmaceutical Chemistry and Applications
- Chemical Synthesis and Analysis
- Monoclonal and Polyclonal Antibodies Research
- HER2/EGFR in Cancer Research
- Innovative Microfluidic and Catalytic Techniques Innovation
- Biosimilars and Bioanalytical Methods
- Advanced Biosensing Techniques and Applications
- bioluminescence and chemiluminescence research
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
The antibody-drug conjugate (ADC) is a well-validated modality for the cell-specific delivery of small molecules with impact expanding rapidly beyond their originally-intended purpose treating cancer. However, antibody-mediated (AMD) remains inefficient, limiting its applicability to targeting highly potent payloads cells high antigen expression. Maximizing number delivered per antibody one key way in which efficiency can be improved, although this has been challenging carry out; few...
Abstract Key defining attributes of an antibody–drug conjugate (ADC) include the choice targeting antibody, linker, payload, and drug-to-antibody ratio (DAR). Historically, most ADC platforms have used same DAR for all targets, regardless target characteristics. However, recent studies modeling suggest that optimal can depend on expression level intratumoral heterogeneity, internalization trafficking, characteristics linker payload. An platform enables optimization could improve success rate...
<p>Table S4 compares the nominal DAR to calculated values from measured Cmax for each ADC</p>
<p>Table S3 contains response numbers for in vivo efficacy study</p>
<p>Complete synthetic route for Monomeric Dolasynthen linker-scaffold-payload</p>
<p>Complete synthetic route for Monomeric Dolasynthen linker-scaffold-payload</p>
<p>Figure S1 shows SEC and HIC overlays for all ADCs compared to their parent antibodies</p>
<p>Table S1 contains measured DARs for ADCs used</p>
<p>Table S4 compares the nominal DAR to calculated values from measured Cmax for each ADC</p>
<p>Figure S3 shows body weights of animals at two doses</p>
<p>Table S2 supplies IC50 values for ADCs over a range of in vitro cytotox assays</p>
<p>Figure S3 shows body weights of animals at two doses</p>
<div>Abstract<p>Key defining attributes of an antibody–drug conjugate (ADC) include the choice targeting antibody, linker, payload, and drug‐to‐antibody ratio (DAR). Historically, most ADC platforms have used same DAR for all targets, regardless target characteristics. However, recent studies modeling suggest that optimal can depend on expression level intratumoral heterogeneity, internalization trafficking, characteristics linker payload. An platform enables optimization could...
<div>Abstract<p>Key defining attributes of an antibody–drug conjugate (ADC) include the choice targeting antibody, linker, payload, and drug‐to‐antibody ratio (DAR). Historically, most ADC platforms have used same DAR for all targets, regardless target characteristics. However, recent studies modeling suggest that optimal can depend on expression level intratumoral heterogeneity, internalization trafficking, characteristics linker payload. An platform enables optimization could...
<p>Figure S2 shows a graphical representation of IC50 spread over range cytotoxicity experiments</p>
<p>Figure S4 compares the body weights of mice dosed with DAR2 and DAR18 ADCs at matched payload antibody doses</p>
<p>Figure S4 compares the body weights of mice dosed with DAR2 and DAR18 ADCs at matched payload antibody doses</p>
<p>Figure S2 shows a graphical representation of IC50 spread over range cytotoxicity experiments</p>
<p>Table S2 supplies IC50 values for ADCs over a range of in vitro cytotox assays</p>
<p>Table S1 contains measured DARs for ADCs used</p>
<p>Figure S1 shows SEC and HIC overlays for all ADCs compared to their parent antibodies</p>
<p>Table S3 contains response numbers for in vivo efficacy study</p>